Oasmia S.A.'s commitment to subscribe for shares in Oasmia Pharmaceutical AB's


Uppsala, Sweden, 2009-08-25                                                    

PRESS RELEASE                                                                   

Oasmia S.A.'s commitment to subscribe for shares in Oasmia Pharmaceutical AB's  
(publ) rights issue                                                             
                                                                                
Oasmia S.A. (the ”Principal Owner”) has committed to subscribe for its share of 
Oasmia Pharmaceutical AB's (publ) (”Oasmia”) rights issue (the “Rights issue”), 
i.e. 70.2 percent of the total volume or 1,680,490 shares, corresponding to     
approximately SEK 42.0 million. The Principal Owner's holding of shares in      
Oasmia is separated into two blocks, through which the total subscription       
commitment of SEK 42.0 million is divided in SEK 12.6 million and SEK 29.4      
million per block respectively.                                                 
                                                                                
The subscription rights relating to the subscription commitment of SEK 12.6     
million have, by mistake, been sold in the market by the Principal Owner's bank.
Hence, the Principal Owner did not, at the end of the subscription period on 24 
August 2009, own these subscription rights and could, as a consequence, not     
fully fulfill its commitment to subscribe for shares.                           
                                                                                
The Principal Owner has taken the following measure to ascertain that Oasmia    
will not be financially worse off than if the SEK 12.6 million subscription     
commitment would have been possible to fulfill:                                 

-  The Principal Owner has applied for subscription of shares in the amount of
SEK 12.6 million without exercise of subscription rights in addition to
subscribing for shares in the amount of SEK 29.4 million through exercise of
subscription rights. The subscription amount of SEK 12.6 million without
exercise of subscription rights corresponds to the subscription that would have
been made if some of the subscription rights would not have been sold. 

The Principal Owner believes that this measure should compensate for any        
possible negative effects resulting from the Principal Owner's inability to     
fully fulfill its subscription commitment.                                      
                                                                                
In addition to the above, and at the same time, the Principal Owner has decided 
to put a credit facility of SEK 30.0 million at Oasmia's disposal. The credit   
facility is available as from today's date and it can be claimed at any time by 
Oasmia. The initial time to maturity is twelve months and the interest rate is  
five per cent.                                                                  

About Oasmia                                                                    
Oasmia Pharmaceutical AB develops second and third generation cancer drugs based
on nanotechnology for human and veterinary use. The broad portfolio is focused  
on oncology and contains several promising products in clinical and pre-clinical
phase. Oasmia cooperates with leading universities and other biotech companies  
to discover and optimize substances with a favourable safety profile and better 
efficacy. The company name was registered in 1999 and is based in Uppsala,      
Sweden.                                                                         



For more information, please contact: Maria Lundén, Head of Public Relations,   
Oasmia Pharmaceutical AB.                                                       
E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also        
available at www.ngm.se and www.oasmia.com

Attachments

oasmia sa commitment rights issue.pdf